Author(s):
Ketan B. Ramani, Vipul Patel
Email(s):
ketanbramani@gmail.com
DOI:
10.5958/0974-360X.2021.00018.4 
Address:
Ketan B. Ramani1*, Dr. Vipul Patel2
1Research Scholar, School of Pharmacy, RK University, Rajkot, Gujarat, India.
2Associate Professor, School of Pharmacy, RK University, Rajkot, Gujarat, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 1,
Year - 2021
ABSTRACT:
Pharmaceutical industries, particularly small and medium scale enterprises (SMEs) always prefer a manufacturing process that involves conventional equipment and devoid of solvents due to commercial, safety and ecological reasons. However, some drug products like Posaconazole delayed-release tablets are currently manufactured by the processes that require complex/ costly equipment or a huge quantity of solvent and specifically skilled personnel. Aim of this study was to simplify delayed-release dosage form of Posaconazole, a BCS class IV drug having pH dependent solubility by the simple yet innovative manufacturing process. The study employed high shear melt granulation (HSMG) technique for manufacturing of drug product. Drug release controlling excipients namely Eudragit L100, triethylcitrate and Macrogol 6000 were selected, as these are suitable excipients for solventless processing at high temperature. Levels of drug release controlling ingredients were optimized using one factor at a time (OFAT) approach. Itwas revealed that drug release from the formulation was affected by the level of Eudragit L100, and Eudragit L100: Macrogol 6000 ratio. The optimized formulation was found satisfactory and reproducible with respect to all the studied pharmacotechnical parameters. The product was found stable at the accelerated storage conditions. In conclusion, Posaconazole delayed-release tablets can be prepared by conventional set of equipment, which are available at most of the pharmaceutical SME by using the explored HSMG technique.
Cite this article:
Ketan B. Ramani, Vipul Patel. Development of Posaconazole delayed-release tablets by high shear melt Granulation Technique. Research J. Pharm. and Tech. 2021; 14(1):96-102. doi: 10.5958/0974-360X.2021.00018.4
Cite(Electronic):
Ketan B. Ramani, Vipul Patel. Development of Posaconazole delayed-release tablets by high shear melt Granulation Technique. Research J. Pharm. and Tech. 2021; 14(1):96-102. doi: 10.5958/0974-360X.2021.00018.4 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-18
REFERENCES:
1. Dave R, Vyasa B, Daniel P, Anand I, Patel C. A Review on Posaconazole: A Newer Antifungal. Research J Pharm and Tech. 2010;3(3):694-699.
2. USFDA Label of Noxafil (Posaconazole). https://www.accessdata. fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf.
3. Fang LY, Harris D, Krishna G, et al. High-density compositions containing posaconazole and formulations comprising the same. https://patents.google.com/patent/WO2009129300A2/en. Accessed January 18, 2020.
4. Sharpe S, Sequeira J, Harris D, Mahashabde S. Antifungal composition with enhanced boavailability. March 2003. https://patents. google.com/patent/US20030055067. Accessed January 18, 2019.
5. Kulkarni SK, Mehta PR, Kapoor R, Maheshwari RKB. Delayed-release posaconazole tablets. :5. https://patents.google.com/patent/ US20150231081A1/en?oq=US20150231081A1. Accessed January 18, 2019.
6. Guillan MG, Nieto LN, Fernandez LA, Calzada JV. Pharmaceutical composition comprising amorphous posaconazole. https://patents.google.com/patent/WO2017032908A1/en?oq=WO2017032908A1. Accessed January 18, 2019.
7. Wan J, Sheng X. Posaconazole pharmaceutical compositions and preparation methods, uses and pharmaceutical formulations thereof. July 2018. https://patents.google.com/patent/US10022373B2/en.
8. Prathap VR, Kalamata VN, Rallabandi BRC, Hendrik S, Ansgar F. Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor. August 2017. https://patents.google.com/patent/ EP3210599A1/en?oq=EP3210599A1
9. Jiansheng W, Kun L, Xiaoqian S. Posaconazole pharmaceutical composition and preparation method, application and pharmaceutical preparation thereof. October 2015. https://patents.google.com/patent/ WO2015154718A1/en. Accessed February 21, 2020.
10. Kathuria A, Asgarzadeh F, Engels S, Jensen B. Enteric Protection for Multi-particulates Using Eudragit® L 100 and Eudragit® S 100 Polymers in a Novel Rotor Granulation Dry Coating Process. In: Poster #R6141. AAPS Annual Meeting & Exposition; 2011.
11. Wong T, Cheong W, Hang P. Melt Granulation and Pelletization. In: Handbook of Pharmaceutical Granulation Technology - Edited by Dilip M. Parikh. 2nd ed. USA: Taylor & Francis Group; 2005:385-406.
12. Shanmugam S. Granulation techniques and technologies: recent progresses. Bioimpacts. 2017;5(1):55-63. doi:10.15171/bi.2015.04
13. Desai U, Chaudhari P, Bhavsar D, Chavan R. Melt granulation: An alternative to traditional granulation techniques. Indian Drugs. 2013; 50: 5-13.
14. Bhagwat DA, Kawtikwar PS, Sakarkar DM. Sustained release matrices of Verapamil HCl using glyceryl monosterate and stearic acid. Research J Pharm and Tech. 2008;1(4):405-409.
15. Mahaparale PR, Kuchekar BS. Sustained release wax matrix tablet of Metoprolol succinate. Research J Pharm and Tech. 2012;5(11):1408-1412.
16. Patil M, Keny R, Pimprikar R, et al. Physicochemical Characterization of Solid Dispersion of Telmisartan with Alkaliser by Hot Melt Method. Research Journal of Pharmaceutical Dosage Forms and Technology. 2009;1(3):250-253.
17. Punitha S, Srinivasa Reddy G, Srikrishna T, Lakshman Kumar M. Solid Dispersions: A Review. Research Journal of Pharmacy and Technology. 2011;4(3):331-334.
18. Chitlange SS, Pawbake GR, S.V. Pandkar, S.B. Wankhede. Formulation and Evaluation of Diacerein Solid Dispersion for Solubility and Dissolution Rate Enhancement. Research Journal of Pharmacy and Technology. 2011;4(6):932-937.
19. Pradeep NS. A Review: Increasing Solubility of Poorly Soluble Drugs, by Solid Dispersion Technique. Research Journal of Pharmacy and Technology. 2011;4(12):1933-1940.
20. Jadhav YL, Parashar B, Ostwal PP, Jain MS. Solid Dispersion: Solubility Enhancement for Poorly Water-Soluble Drug. Research Journal of Pharmacy and Technology. 2012;5(2):190-197.
21. Bhore SD. A Review on Solid Dispersion as a Technique for Enhancement of Bioavailability of Poorly Water-Soluble Drugs. Research Journal of Pharmacy and Technology. 2014;7(12):1485-1491.
22. Wagh MP, Bele MH, Patel JS, Pawar AY. Alternative Strategies in Solid Dispersion Manufacturing. Research Journal of Pharmaceutical Dosage Forms and Technology. 2010;2(1):14-22.
23. Shaikh MV, Thube R. Solubility enhancement of Aceclofenac by hot melt solid dispersion technique. Research J Pharm and Tech. 2011; 4(8): 1307-1310.
24. Hajare A, Shetty Y, Mali M, Sarvagod S. Characterization of Melt (Fusion) Solid Dispersions of Nifedipine. Research Journal of Pharmacy and Technology. 2008;1(3):230-234.
25. Bitencourt AS, Oliveira SS, Mendez ASL, Garcia CV. UV Spectrophotometric method for determination of posaconazole: Comparison to HPLC. Journal of Basic and Applied Pharmaceutical Sciences. 2015;36(4):491-495.
26. Dissolution Methods. https://www.accessdata.fda.gov/scripts/CDER/ dissolution/dsp_SearchResults.cfm. Accessed February 22, 2020.
27. Bioavailability studies submitted in NDA or INDs - General considerations: Appendix C: Guidelines for conducting in-vitro alcohol dose-dumping study. https://www.fda.gov/media/121311/download. Accessed February 9, 2020.
28. Friebe TP, Asgarzadeh F, Gray A, et al. Regulatory Considerations for Alcohol-Induced Dose Dumping of Oral Modified-Release Formulations. Pharmaceutical Technology. 2015;38(10):40-46.